IonQ reaches 1,000 patents milestone with new quantum computing grants
Mary Beth Fritz, Senior Vice President of Quality & Regulatory at Prestige Consumer Healthcare Inc. (NYSE:PBH), has sold 1,678 shares of the company’s common stock. The transaction, which took place on March 10, 2025, was executed at a price of $90.00 per share, amounting to a total value of $151,020. Following this sale, Fritz retains ownership of 17,157 shares in the company. The transaction was conducted under a pre-established trading plan, often referred to as a 10b5-1 plan. Trading near its 52-week high of $90.04, the stock appears slightly overvalued according to InvestingPro Fair Value calculations. Discover more insights and 5 additional ProTips with an InvestingPro subscription.
In other recent news, Prestige Brands announced third-quarter sales and earnings per share (EPS) that exceeded expectations, leading to an increase in its full-year 2025 EPS guidance to approximately $4.50 from the previous range of $4.40 to $4.46. Following this announcement, DA Davidson analyst Linda Bolton Weiser raised the price target for Prestige Brands to $104 from $95, maintaining a Buy rating. The company’s strong performance was supported by increased sales of Summer’s Eve products and a rise in Clear Eyes shipments. Looking ahead, Prestige Brands plans to expand its supplier base for Clear Eyes in the second half of fiscal year 2026.
Additionally, Canaccord Genuity reiterated its Buy rating on Prestige Brands, maintaining a price target of $93. The firm highlighted the company’s strategic financial management and growth initiatives, including capital allocation strategies focused on reinvestment, mergers and acquisitions, and debt reduction. Prestige Brands’ management emphasized their commitment to operational enhancements and supplier diversification during a recent discussion with Canaccord. The analysts at Canaccord also suggested that Prestige Brands is well-positioned for potential accretive mergers and acquisitions within the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.